Stroke Therapy Academic Industry Roundtable (STAIR) meetings

I wish I could figure out a way to get invited to these meetings. They are definitely way too insular and need a devils advocate.

• STAIR is an invitation only conference, which assembles a select group of leading scientists from industry, academia and government.(why scientists only?)
  

Who has written updates from these meetings that they can send me?
Ok,here are the writeups; interesting to read but not written for the layman, At least someone is working on a lot of the cascade of death items I've written about, it just took two years to find out that scientists are working on it in silence.
http://www.thestair.org/Public/Publications/index.htm
Here is the org;
http://www.thestair.org/

The STAIR meetings bring together stroke neurologists and other physicians, industry representatives and regulators to discuss issues related to the development of new stroke therapies. The first five STAIR meetings generated recommendations for the preclinical evaluation of stroke therapies, phase II and phase III trial design, enhancing trial implementation and completion, novel approaches to measuring outcome and regulatory considerations. The impact of these recommendations from the prior STAIR meetings has been substantial, but successful development of new therapies remains highly challenging, necessitating reconsideration and refinement. This report, which is based on expert opinion from the meeting and consideration of information not available at the time of the meeting but subsequently released and of critical importance to this topic, provides recommendations for enhancing clinical trials utilizing longer therapeutic time windows.

Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations

http://stroke.ahajournals.org/content/40/6/2244.abstract

Abstract

The initial Stroke Therapy Academic Industry Roundtable (STAIR) recommendations published in 1999 were intended to improve the quality of preclinical studies of purported acute stroke therapies. Although recognized as reasonable, they have not been closely followed nor rigorously validated. Substantial advances have occurred regarding the appropriate quality and breadth of preclinical testing for candidate acute stroke therapies for better clinical translation. The updated STAIR preclinical recommendations reinforce the previous suggestions that reproducibly defining dose response and time windows with both histological and functional outcomes in multiple animal species with appropriate physiological monitoring is appropriate. The updated STAIR recommendations include: the fundamentals of good scientific inquiry should be followed by eliminating randomization and assessment bias, a priori defining inclusion/exclusion criteria, performing appropriate power and sample size calculations, and disclosing potential conflicts of interest. After initial evaluations in young, healthy male animals, further studies should be performed in females, aged animals, and animals with comorbid conditions such as hypertension, diabetes, and hypercholesterolemia. Another consideration is the use of clinically relevant biomarkers in animal studies. Although the recommendations cannot be validated until effective therapies based on them emerge from clinical trials, it is hoped that adherence to them might enhance the chances for success.

If I had known about this earlier I could have used this to talk to the ASA,NSA and WSO and ask what they are doing to publicize this work. I'm just a laboratory rat and shouldn't try to go above my station in life